The European pharmaceutical landscape is undergoing significant regulatory and research-driven changes. Vifor Pharma’s recent clash with the European Commission, coupled with groundbreaking diabetes research, marks a pivotal moment for healthcare stakeholders. This article delves into these major d
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasingly recognized for its significant health and economic impacts. Characterized by excessive fat accumulation in the liver, MASLD can escalate to more severe
The use of biosimilars in oncology promises significant cost savings and improved access to cancer treatments. However, despite their demonstrated efficacy and safety, several obstacles stand in the way of their widespread adoption. This article delves into the key barriers preventing the broader
Oncology drug development has undergone a remarkable transformation in recent years, driven by advances in precision medicine and an increasing emphasis on patient-centered approaches. This shift is not just about creating more effective treatments but also about ensuring these treatments address
In recent years, the field of gene therapy has made remarkable advancements, notably in addressing genetic hearing loss in children. Innovative therapies aimed at correcting otoferlin deficiencies have emerged as a beacon of hope, offering potential solutions that surpass traditional hearing aids
Bluebird Bio, a notable player in the gene therapy field, is grappling with early challenges in the launch of its approved gene therapies, particularly for its sickle cell disease (SCD) treatment, Lyfgenia. Despite gaining regulatory approval alongside its competitor Vertex Pharmaceuticals
